Microdosing a GLP-1: the term has no label, and a tablet cannot be split

Before you read. This page explains what the FDA labels and the FDA's own compounding alerts say. It is educational and is emphatically not a guide to dosing outside a label. Dose decisions belong to your prescriber, the labels cap intake at one tablet per day, and taking a dose that was not measured out by a licensed process is how the dosing errors described below happen. If your reason for reading this is that a dose is hard to tolerate, the last section is the one written for you.

Quick answer

There is no such thing as a microdose in a drug label. No FDA-approved GLP-1 product defines one, prints one, or supplies one. The term comes from practice and marketing, not from labelling, so it means whatever the person using it means.

For the oral tablets, one instruction settles the mechanical version of the question in a single line:

Swallow tablets whole. Do not split, crush, chew or dissolve in any solution.

That is not a preference. Oral semaglutide is co-formulated with an absorption enhancer, and the tablet is a delivery mechanism rather than a container. Break it and you have not halved the dose; you have interfered with the thing that lets any of it be absorbed at all.

The lowest labelled doses already exist, and they are lower than most people realise — 1.5 mg for Ozempic and Wegovy tablets, 0.8 mg for Foundayo. What the labels also say is that the bottom rung is an initiation step rather than a treatment.

And if tolerability is the real question underneath, the labels contain a provision for it that most people have never been shown. It is in the last section.

Keep the ladder for the drug you actually take →

What people mean by it

The word is doing three different jobs, and they need separating before any of them can be answered.

Taking less than the labelled maintenance dose. Which is not exotic at all — it is what everyone does for the first sixty days of a ladder, by instruction.

Staying on a low dose indefinitely rather than climbing. A real clinical pattern, and a prescriber's decision to make.

Measuring out a fraction of a labelled dose yourself. Splitting a tablet, or drawing a smaller volume from a vial. This is the version that carries risk, and it is the version most of the online discussion is actually about.

Almost all of that discussion concerns compounded injectables, where a vial and a syringe make fractional dosing physically easy. The oral tablets are a different object, and that difference is the whole of the next section.

Why half a tablet is not half a dose

Here is the mechanism, and it is unusual enough to be worth reading slowly.

Estimated absolute bioavailability of semaglutide tablets is 0.4% to 1%. Under one hundredth of what you swallow reaches the bloodstream. The reason any of it does is SNAC — salcaprozate sodium, co-formulated into the tablet — which the label describes as facilitating the absorption of semaglutide after oral administration. And the absorption predominantly occurs in the stomach, not further down the gut where most swallowed drugs are taken up.

Put those together. A semaglutide tablet works by creating a brief, local, high concentration of drug and enhancer together at the stomach wall, in a small window, before the stomach does what stomachs do to peptides. It is not a quantity of drug that happens to be pressed into a disc.

Splitting it changes the geometry of that event: the ratio of drug to enhancer at the surface, the dissolution behaviour, the local concentration. Nothing in the label supports the assumption that the result is a proportional dose, and no study of a split tablet appears anywhere in it. The dose-proportionality the label reports was measured across whole tablets at labelled strengths.

Which is why the instruction is worded the way it is — swallow whole, do not split, crush, chew or dissolve — and why it sits in the same short list as "do not take more than one tablet per day." Why so little of each tablet gets in covers the mechanism in full, and what each broken morning costs covers the other ways the window gets lost.

The asymmetry worth noticing. With an injection, a smaller volume is a smaller dose in a way that is at least arithmetically clean, whatever else is wrong with measuring it yourself. With this tablet it is not even arithmetic — the delivery system is part of the dose. That makes oral GLP-1s the one form where the mechanical version of microdosing is ruled out by the pharmacology rather than only by the instruction.

The lowest doses that actually exist

If the goal is simply "start low," the labels are lower than the conversation assumes.

Product	Lowest labelled strength	What the label calls it
Ozempic tablets	1.5 mg	Starting dosage, days 1–30
Wegovy tablets	1.5 mg	Starting dosage, days 1–30
Rybelsus	3 mg	Starting dosage, days 1–30, stated as not effective for glycemic control
Foundayo (orforglipron)	0.8 mg	First of six steps, 30 days each

Foundayo's ladder is the longest of the four — six strengths from 0.8 mg to 17.2 mg, each held for 30 days, and the six-step Foundayo ladder lays it out. A drug with six rungs is already doing, by design, what a gentler climb is meant to achieve.

The label already says the lowest dose does not do the job

This is the sentence that complicates the appealing version of microdosing, and it is right there in the dosage section:

Day 1 to 30: Recommended starting dosage is 3 mg orally once daily for 30 days (this dosage is not effective for glycemic control)

The bottom rung is not a small treatment. It is a tolerance step whose stated purpose is to let the gut adjust before a therapeutic dose starts.

So "stay on the lowest dose and get a gentler version of the benefit" is not a claim the label supports for oral semaglutide. It supports the opposite: that the lowest dose is not doing the licensed job. Whether some effect is present at that dose is a question the label does not answer, because the trials were not designed to ask it. Day 30, day 60, week 26 sets out what the schedule actually is.

A ladder you half-remember is where dose mistakes come from. Takely asks which medicine you are on and shows only that medicine's steps, with the 30-day holds where the label puts them. Open Takely in your browser →

What the FDA has said about the compounded version

Most microdosing in practice happens with compounded semaglutide, and the FDA's position on it is a matter of public record rather than of opinion.

Compounded drug products are not FDA-approved. They do not undergo FDA premarket review for safety, effectiveness or quality, which the agency describes as making them a higher risk to patients than approved drugs. The FDA's stated position is that compounded drugs should be used only for patients whose medical needs cannot be met by an available FDA-approved drug.

More directly relevant here: the FDA has issued an alert about dosing errors associated with compounded injectable semaglutide products, having received reports of adverse events that may relate to overdoses — including severe nausea, severe vomiting and severe hypoglycaemia. In September 2025 it issued warning letters to multiple compounders, including for false or misleading claims that their products were equivalent to the approved ones.

Dosing errors are the specific failure mode of fractional dosing. A dose that has to be measured by hand is a dose that can be mismeasured, and the reported consequences are at the severe end of the same reactions the labels already list.

If tolerability is the reason, the labels have a provision for it

Most people arrive at this topic through a real problem: the dose is hard to take. That problem has a labelled answer, and it is not a smaller tablet.

The 30-day hold is the go-slow mechanism. Each ladder step is held for thirty days specifically to reduce the risk of gastrointestinal adverse reactions. The label ties those reactions to escalation directly, and reports that the majority of nausea, vomiting and diarrhoea occurred during dose escalation. Why escalation weeks are when most of this happens goes through the pattern.

Escalation can be delayed. The Wegovy label says it explicitly: if patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation. That is the labelled version of going slower — staying longer on a rung, rather than inventing a rung between two.

14 mg is conditional, not a destination. The Rybelsus ladder increases to 14 mg only if additional glycemic control is needed. A stable 7 mg is a complete treatment for the people it suits.

Those three provisions cover most of what microdosing is reaching for, and they have the advantage of existing in the document your prescriber is working from. The conversation to have is about the pace of the ladder — which is a request a prescriber can act on, and one the label anticipates.

Frequently asked questions

Can you split a Rybelsus tablet in half?

No. The label instructs that tablets be swallowed whole and not split, crushed, chewed or dissolved in any solution. The tablet is co-formulated with an absorption enhancer and absorbed in the stomach through a narrow window, so a split tablet is not a proportionally smaller dose — and no study of one appears in the label.

What is microdosing a GLP-1?

It is not a labelled term. No FDA-approved GLP-1 product defines or supplies a microdose. In practice it usually means taking less than a labelled maintenance dose, and most often refers to fractional doses of compounded injectable products rather than to anything printed on an approved label.

What is the smallest dose of oral semaglutide?

Rybelsus starts at 3 mg; Ozempic tablets and Wegovy tablets start at 1.5 mg. All three are 30-day starting dosages, and the Rybelsus label states in parentheses that its 3 mg dose is not effective for glycemic control.

Is a low dose safer?

The label's gastrointestinal figures do rise with dose within a product, and the ladder exists because of it. What the labels do not offer is a low dose described as a maintenance treatment — the lowest rungs are initiation steps. Which dose is right for you is a prescriber's judgement rather than a general rule.

Is compounded semaglutide the same as the approved product?

The FDA's position is that compounded drugs are not FDA-approved and do not undergo premarket review for safety, effectiveness or quality, and it has issued warning letters over claims of equivalence to the approved products. It has also alerted providers and patients to dosing errors with compounded injectable semaglutide, with reported adverse events including severe nausea, severe vomiting and severe hypoglycaemia.

What should I ask if the dose is too much for me?

Ask about the pace rather than the size. The labels hold each step for 30 days, one of them explicitly says to consider delaying escalation if a dose is not tolerated, and the top rung of the Rybelsus ladder is conditional on whether more glycemic control is needed. Those are all things a prescriber can adjust within the label.

Primary sources and further reading

Labels and agency alerts are both revised. Everything above was read off those sources on 8 September 2026.